Filters

2014 - 20152

More filters

20192
Reset filters

Settings

Subject: biomarkers × WGL Institute: ISAS ×

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Highly immunoreactive IgG antibodies directed against a set of twenty human proteins in the sera of patients with amyotrophic lateral sclerosis identified by protein array
    (San Francisco, CA : Public Library of Science, 2014) May, Caroline; Nordhoff, Eckhard; Casjens, Swaantje; Turewicz, Michael; Eisenacher, Martin; Gold, Ralf; Brüning, Thomas; Pesch, Beate; Stephan, Christian; Woitalla, Dirk; Penke, Botond; Janáky, Tamás; Virók, Dezső; Siklós, László; Engelhardt, Jozsef I.; Meyer, Helmut E.
    Amyotrophic lateral sclerosis (ALS), the most common adult-onset motor neuron disorder, is characterized by the progressive and selective loss of upper and lower motor neurons. Diagnosis of this disorder is based on clinical assessment, and the average survival time is less than 3 years. Injections of IgG from ALS patients into mice are known to specifically mark motor neurons. Moreover, IgG has been found in upper and lower motor neurons in ALS patients. These results led us to perform a case-control study using human protein microarrays to identify the antibody profiles of serum samples from 20 ALS patients and 20 healthy controls. We demonstrated high levels of 20 IgG antibodies that distinguished the patients from the controls. These findings suggest that a panel of antibodies may serve as a potential diagnostic biomarker for ALS.
  • Thumbnail Image
    Item
    Current strategies and findings in clinically relevant post-translational modification-specific proteomics
    (Milton Park : Taylor & Francis, 2015) Pagel, Oliver; Loroch, Stefan; Sickmann, Albert; Zahedi, René P.
    Mass spectrometry-based proteomics has considerably extended our knowledge about the occurrence and dynamics of protein post-translational modifications (PTMs). So far, quantitative proteomics has been mainly used to study PTM regulation in cell culture models, providing new insights into the role of aberrant PTM patterns in human disease. However, continuous technological and methodical developments have paved the way for an increasing number of PTM-specific proteomic studies using clinical samples, often limited in sample amount. Thus, quantitative proteomics holds a great potential to discover, validate and accurately quantify biomarkers in body fluids and primary tissues. A major effort will be to improve the complete integration of robust but sensitive proteomics technology to clinical environments. Here, we discuss PTMs that are relevant for clinical research, with a focus on phosphorylation, glycosylation and proteolytic cleavage; furthermore, we give an overview on the current developments and novel findings in mass spectrometry-based PTM research.